Valneva (NASDAQ:VALN) Shares Gap Down – Here’s Why

Valneva SE Sponsored ADR (NASDAQ:VALN)’s share price gapped down prior to trading on Wednesday . The stock had previously closed at $5.76, but opened at $5.58. Valneva shares last traded at $5.8560, with a volume of 13,252 shares trading hands.

Analysts Set New Price Targets

VALN has been the topic of several recent analyst reports. The Goldman Sachs Group lowered Valneva from a “neutral” rating to a “sell” rating and set a $4.90 price target on the stock. in a research note on Wednesday, April 22nd. Guggenheim set a $11.00 price target on Valneva in a research note on Thursday, April 16th. Finally, Wall Street Zen raised Valneva from a “strong sell” rating to a “sell” rating in a research note on Saturday. Three research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Valneva has an average rating of “Hold” and an average target price of $11.98.

Valneva Stock Up 2.9%

The business has a 50-day simple moving average of $6.88 and a 200-day simple moving average of $8.54. The company has a market cap of $562.22 million, a price-to-earnings ratio of -3.17 and a beta of 1.72. The company has a debt-to-equity ratio of 2.14, a quick ratio of 1.60 and a current ratio of 2.14.

Valneva (NASDAQ:VALN) last released its quarterly earnings results on Tuesday, March 31st. The company reported ($0.42) earnings per share (EPS) for the quarter. The firm had revenue of $35.77 million for the quarter. Valneva had a negative return on equity of 107.63% and a negative net margin of 88.87%. On average, equities analysts anticipate that Valneva SE Sponsored ADR will post -1 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of VALN. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Valneva in the 4th quarter valued at approximately $44,000. VSM Wealth Advisory LLC raised its holdings in shares of Valneva by 125.0% in the third quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock worth $110,000 after acquiring an additional 5,000 shares during the last quarter. JPMorgan Chase & Co. acquired a new position in shares of Valneva in the third quarter worth $124,000. XTX Topco Ltd purchased a new stake in shares of Valneva in the fourth quarter valued at $94,000. Finally, Marex Group plc purchased a new stake in shares of Valneva in the second quarter valued at $64,000. 11.39% of the stock is currently owned by hedge funds and other institutional investors.

About Valneva

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.